Aldosterone receptor antagonists: current perspectives and therapies

Item

http://www.wikidata.org/entity/Q38120241

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Aldosterone receptor antagonists: current perspectives and therapies

@en

type

Item

label

Aldosterone receptor antagonists: current perspectives and therapies

@en

prefLabel

Aldosterone receptor antagonists: current perspectives and therapies

@en

P1476

Aldosterone receptor antagonists: current perspectives and therapies

@en

P2093

David A Calhoun

http://www.w3.org/2001/XMLSchema#string

Donald Clark

http://www.w3.org/2001/XMLSchema#string

Jason L Guichard

http://www.w3.org/2001/XMLSchema#string

Mustafa I Ahmed

http://www.w3.org/2001/XMLSchema#string

P2860

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

High prevalence of unrecognized sleep apnoea in drug-resistant hypertension

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study

New insights into the pharmacokinetics of spironolactone.

Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.

Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

P304

321-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/VHRM.S33759

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23836977

http://www.w3.org/2001/XMLSchema#string

P921

aldosterone

Nuclear receptor subfamily 3 group C member 2

Renin–angiotensin system

P932

3699348

http://www.w3.org/2001/XMLSchema#string